Moreover, the additive inhibitory effect of ruxolitinib on human dendritic cells and CD8+ T cells may underlie its therapeutic efficacy in conditions such as graft-versus-host disease (GVHD) and myeloproliferative disorders and may open new avenues for therapeutic applications targeting immune cell trafficking. This evidence concerns the gene CD8A and graft versus host disease.